SCHEDULE 13G: Goldman Sachs Discloses 6.0% Stake in Nevro Corp. Common Stock
Beneficial Ownership Disclosure
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have jointly filed a Schedule 13G, disclosing beneficial ownership of 6.0% of Nevro Corp.'s common stock as of March 31, 2025.
Summary
- The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC collectively beneficially own 2,306,137.55 shares of Nevro Corp. Common Stock.
- This aggregate amount represents 6.0% of Nevro Corp.'s outstanding common stock.
- The beneficial ownership includes 2,305,870.55 shares with shared voting power and 2,306,137.55 shares with shared dispositive power.
- The filing was made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- The Goldman Sachs Group, Inc. is classified as a parent holding company, and Goldman Sachs & Co. LLC is classified as a broker or dealer and an investment adviser.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative statements or performance metrics that would indicate a positive or negative sentiment. It is neutral in tone and content.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment by Goldman Sachs in Nevro Corp., a company operating in the medical device sector, specifically known for its neuromodulation platforms. Such a substantial stake by a major financial institution can signal confidence in the company's long-term prospects or its position within the healthcare technology industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like Goldman Sachs may be viewed positively by existing shareholders, potentially signaling institutional confidence in Nevro Corp.
Key Dates
| Date | Description |
|---|---|
| 2023-12-01 | Superseded Power of Attorney granted by Goldman Sachs & Co. LLC. |
| 2024-02-09 | Superseded Power of Attorney granted by The Goldman Sachs Group, Inc. |
| 2024-07-29 | Date of Power of Attorney for The Goldman Sachs Group, Inc., effective until July 29, 2025. |
| 2024-10-01 | Date of Power of Attorney for Goldman Sachs & Co. LLC, effective until October 1, 2025. |
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership threshold met). |
| 2025-05-05 | Date of filing of the Schedule 13G and Joint Filing Agreement. |
Keywords
Nevro Corp., Goldman Sachs Group Inc., Goldman Sachs & Co. LLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.